GENEDX HOLDINGS (WGS)
(Delayed Data from NSDQ)
$32.72 USD
-1.12 (-3.31%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $32.88 +0.16 (0.49%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth C Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
WGS 32.72 -1.12(-3.31%)
Will WGS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for WGS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for WGS
Best Momentum Stocks to Buy for July 23rd
New Strong Buy Stocks for July 23rd
WGS: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes GeneDx Holdings Corp. (WGS) a Strong Momentum Stock: Buy Now?
Small Caps Climb on Interest Rate Cut Expectations: 5 Picks
Zacks.com featured highlights include Daktronics, Hess, Advanced Drainage Systems, Apogee and GENEDX
Other News for WGS
Healthcare 2024 Second Half Outlook
GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing
Opko Health price target lowered by $2 at Piper Sandler, here's why
Expert Ratings For GeneDx Hldgs
GeneDx to Report Second Quarter 2024 Financial Results on Tuesday, July 30, 2024